40131MAD1
Guardant Health, Inc.
Could not find a ticker for this position, may be a filing error
A precision-oncology company that spots cancer with simple blood tests, including the Shield test, the first FDA-approved blood test for colorectal cancer screening, plus the Guardant360 CDx for guiding treatment and Guardant Reveal for watching for recurrence. Co-founded in 2012 by two Stanford PhDs, Helmy Eltoukhy and AmirAli Talasaz, it was built on the idea of catching cancer's genetic "signature" floating in the bloodstream. Its Shield test was designed to make cancer screening as easy as a routine blood draw, avoiding the preparation many people dread.
CONVERTIBLEUnderlying: GHCUSIP: 40131MAD1HealthcareUS1 derivative reporter
1.25% Convertible Senior Notes due 2031
No tracked superinvestor held this security as stock in this period — only the derivative positions below reference it.
Derivative Reporters
Investor
Kind
13F reported value
Quantity
Change
